Sakeena Syed

Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma

Junling Zhuang, Fazal Shirazi, Ramesh Singh et al. · Blood · 2019 · 74 citations · Full text

MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models

Francesca Vena, Ruochen Jia, Arman Esfandiari et al. · Oncotarget · 2018 · 48 citations · Full text

Abstract 2156: IK-930 is a novel TEAD inhibitor for the treatment of cancers harboring mutations in the Hippo signal transduction pathway

Benjamin Amidon, Marta Sánchez-Martín, Wilmin Bartolini et al. · Cancer Research · 2022 · 17 citations

Tumor Biology, Hippo Pathway, Systems Biology +13

Abstract 2384: TAK-169, an exceptionally potent CD38 targeted engineered toxin body, as a novel direct cell kill approach for the treatment of multiple myeloma

Erin K. Willert, Garrett L. Robinson, Jack P. Higgins et al. · Cancer Research · 2019 · 14 citations

Potent Cd38, Cd38-expressing Cells, Immunology +26

TAK-573, an anti-CD38-targeted attenuated interferon alpha (IFNα) fusion protein, showed anti-myeloma tumor responses in combination with standard of care (SOC) agents in multiple myeloma (MM) xenograft tumor models in vivo

Marjan Fatholahi, Armanini Mark, Mingying Bi et al. · Clinical Lymphoma Myeloma & Leukemia · 2019 · 10 citations